D.E. Shaw & Co
CHRS icon

D.E. Shaw & Co’s Coherus Oncology CHRS Stock Holding History

D.E. Shaw & Co’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-127,610
Closed -$425K – 4386
2023
Q4 		$425K Sell
127,610
-578,798
-82% -$1.55M ﹤0.01% 3593
2023
Q3 		$2.64M Sell
706,408
-430,740
-38% -$1.99M ﹤0.01% 2358
2023
Q2 		$4.86M Buy
1,137,148
+138,770
+14% +$819K 0.01% 1878
2023
Q1 		$6.83M Buy
998,378
+278,552
+39% +$2.16M 0.01% 1683
2022
Q4 		$5.7M Buy
719,826
+124,282
+21% +$956K 0.01% 1965
2022
Q3 		$5.72M Buy
595,544
+48,879
+9% +$495K 0.01% 1939
2022
Q2 		$3.96M Buy
546,665
+180,878
+49% +$1.57M ﹤0.01% 2413
2022
Q1 		$4.72M Buy
365,787
+270,122
+282% +$3.44M ﹤0.01% 2382
2021
Q4 		$1.53M Buy
95,665
+50,998
+114% +$892K ﹤0.01% 3593
2021
Q3 		$718K Sell
44,667
-50,195
-53% -$736K ﹤0.01% 3851
2021
Q2 		$1.31M Sell
94,862
-174,771
-65% -$2.48M ﹤0.01% 3322
2021
Q1 		$3.94M Sell
269,633
-13,937
-5% -$237K ﹤0.01% 2037
2020
Q4 		$4.93M Sell
283,570
-303,064
-52% -$5.4M ﹤0.01% 1882
2020
Q3 		$10.8M Sell
586,634
-253,885
-30% -$4.72M 0.01% 1195
2020
Q2 		$15M Sell
840,519
-601,624
-42% -$10.2M 0.02% 944
2020
Q1 		$23.4M Buy
1,442,143
+337,631
+31% +$6.24M 0.04% 554
2019
Q4 		$19.9M Buy
1,104,512
+726,647
+192% +$13.4M 0.02% 820
2019
Q3 		$7.66M Buy
377,865
+124,142
+49% +$2.48M 0.01% 1348
2019
Q2 		$5.61M Sell
253,723
-52,551
-17% -$913K 0.01% 1511
2019
Q1 		$4.18M Sell
306,274
-71,899
-19% -$959K 0.01% 1655
2018
Q4 		$3.42M Buy
378,173
+91,848
+32% +$1.06M ﹤0.01% 1758
2018
Q3 		$4.72M Buy
286,325
+177,142
+162% +$3.14M 0.01% 1615
2018
Q2 		$1.53M Buy
109,183
+94,042
+621% +$1.35M ﹤0.01% 2421
2018
Q1 		$167K Sell
15,141
-22,965
-60% -$251K ﹤0.01% 3356
2017
Q4 		$336K Sell
38,106
-68,915
-64% -$738K ﹤0.01% 3192
2017
Q3 		$1.43M Sell
107,021
-12,279
-10% -$162K ﹤0.01% 2262
2017
Q2 		$1.71M Sell
119,300
-200,170
-63% -$3.85M ﹤0.01% 2070
2017
Q1 		$6.76M Buy
319,470
+183,012
+134% +$4.5M 0.01% 1091
2016
Q4 		$3.84M Buy
136,458
+34,785
+34% +$973K 0.01% 1508
2016
Q3 		$2.72M Buy
+101,673
New +$2.77M ﹤0.01% 1687

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

D.E. Shaw & Co's CHRS Position: Q1 2024 in Review

D.E. Shaw & Co sold out of Coherus Oncology (CHRS) in Q1 2024, closing a stake of 127,610 shares — an estimated $425K sold.

D.E. Shaw & Co first reported a position in CHRS in Q3 2016 and held it in 30 quarters. The position peaked at $23.4M in Q1 2020. 137 funds tracked by Wall St. Rank hold CHRS as of Q1 2024.

  • D.E. Shaw & Co reported no remaining Coherus Oncology position as of Q1 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 127,610 Coherus Oncology shares in Q1 2024, an estimated $425K.
  • D.E. Shaw & Co first reported a position in Coherus Oncology in Q3 2016 and held it in 30 quarters.
  • D.E. Shaw & Co's Coherus Oncology position peaked at $23.4M in Q1 2020.
  • 137 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2024.

Based on D.E. Shaw & Co's 13F filing for Q1 2024, filed 15 May 2024.